Abstract
Indiplon is a nonbenzodiazepine hypnotic being developed for the treatment of insomnia by Neurocrine Biosciences Inc. It is an allosteric modulator of the γ-amino butyric acid-α receptor complex with very high affinity for the α1 subunit, which is associated with hypnotic activity, sedation and amnesia. Indiplon has been developed in two different formulations: an immediate-release version targeting sleep initiation insomnia and a modified-release version addressing sleep maintenance insomnia. Early results from clinical trials indicate that both formulations are well tolerated and effective at improving objective and subjective measures of sleep.
Disclosure
The author has received payments for consultancies, research, and/or speaker‘s bureau activities from the sponsors whose products are identified in this review: Neurocrine Biosciences, Pfizer, Sanofi-Aventis, Sepracor, Elan, King and Takeda.
Acknowledgement
The author would like to thank Ms Bridget Banas for her assistance in the preparation of this manuscript.